for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sana Biotechnology Inc

SANA.OQ

Latest Trade

21.65USD

Change

-1.36(-5.91%)

Volume

159,160

Today's Range

21.64

 - 

22.90

52 Week Range

16.10

 - 

44.56

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
23.01
Open
22.90
Volume
159,160
3M AVG Volume
18.68
Today's High
22.90
Today's Low
21.64
52 Week High
44.56
52 Week Low
16.10
Shares Out (MIL)
187.89
Market Cap (MIL)
4,067.84
Forward P/E
-10.83
Dividend (Yield %)
--

Latest Developments

More

Sana Biotechnology Reports Q2 2021 Financial Results

Sana Biotechnology Reports Q1 2021 Financial Results

Sana Biotechnology Reports Fourth Quarter And 2020 Financial Results And Business Updates

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sana Biotechnology Inc

Sana Biotechnology, Inc is a preclinical-stage biotechnology company. The Company is focused on creating and delivering engineered cells as medicines for patients. The Company develops in vivo and ex vivo cell engineering platforms for treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system (CNS) disorders, cardiovascular diseases, and genetic disorders, among others. The Company’s process of repairing and controlling genes in the body, referred to as gene therapy or in vivo cell engineering, requires in vivo delivery of a therapeutic payload and modification of the genome. The Company’s fusogen technology in preclinical studies targets cell surface receptors when combined with delivery vehicles to form fusosomes and allows cell-specific delivery across multiple different cell types. It focuses this technology on delivering payloads to T cells, hepatocytes, and hematopoietic stem cells (HSCs).

Industry

Business Services

Contact Info

188 East Blaine Street

Suit 400, Suite 400

SEATTLE, WA

98102

United States

+1.206.7017914

https://sana.com/

Executive Leadership

Hans Edgar Bishop

Independent Chairman of the Board

Steven D. Harr

President, Chief Executive Officer, Director

Nate Hardy

Chief Financial Officer, Executive Vice President

Robin Andrulevich

Chief Human Resource Officer, Chief People Officer

James J. MacDonald

Executive Vice President, General Counsel, Company Secretary

Key Stats

2.25 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2020

0.0K

2021(E)

0.0K
EPS (USD)

2020

-11.560

2021(E)

-1.550
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
4.32
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up